Literature DB >> 8330901

Agonists and antagonists for lipopolysaccharide-induced cytokines.

H D Flad1, H Loppnow, E T Rietschel, A J Ulmer.   

Abstract

Agonistic and antagonistic properties of LPS and partial structures in the induction of cytokines are reviewed. Studies on structure-activity relationships of LPS and lipid A with human mononuclear cells reveal that S- and notably R-form LPS are very potent cytokine inducers. Synthetic E. coli lipid A is somewhat less active, whereas synthetic S. minnesota-type lipid A is significantly less active. Pentaacylated forms of lipid A are less potent than hexaacylated forms, and tetraacylated synthetic precursor Ia and bisacylated disaccharides and monosaccharides are completely inactive, indicating that a structure-dependent hierarchy of LPS and lipid A partial structures determines the monokine-inducing capacity in human mononuclear cells. Precursor Ia is a potent LPS antagonist. The mechanism of its inhibitory activity is shown to be due to competitive binding to cellular binding sites (receptors). Proinflammatory and antiinflammatory cytokines, receptor antagonists, and soluble cytokine receptors influence the cytokine-inducing activity of LPS, suggesting a complex regulatory network.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330901     DOI: 10.1016/S0171-2985(11)80346-3

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  20 in total

1.  Porphyromonas gulae Activates Unprimed and Gamma Interferon-Primed Macrophages via the Pattern Recognition Receptors Toll-Like Receptor 2 (TLR2), TLR4, and NOD2.

Authors:  James A Holden; Neil M O'Brien-Simpson; Jason C Lenzo; Rebecca K H Orth; Ashley Mansell; Eric C Reynolds
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

2.  The polysaccharide portion of lipopolysaccharide regulates antigen-specific T-cell activation via effects on macrophage-mediated antigen processing.

Authors:  N M Zirk; S F Hashmi; H K Ziegler
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14.

Authors:  H Loppnow; F Stelter; U Schönbeck; C Schlüter; M Ernst; C Schütt; H D Flad
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

4.  Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes.

Authors:  B Weidemann; J Schletter; R Dziarski; S Kusumoto; F Stelter; E T Rietschel; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 5.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

6.  Mechanism of three inhibitors of TACE in blocking the converting of pro-TNF alpha into sTNF alpha.

Authors:  Zhen Wang; Yin Wang; Kongli Zhu; Lianjun Guo; Yuzhen Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

7.  Pentoxifylline pretreatment fails to block the acute-phase response to Escherichia coli endotoxin in dwarf goats.

Authors:  C T Van Duin; T Wensing; A S Van Miert
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

Review 8.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

9.  Relationship between the increase of secretion of sTNF alpha induced by lipopolysaccharides and the enhanced expression of TACE mRNA in HL-60 cells and adhesive cells from human spleen.

Authors:  T Ding; L Li; K Zhu; W Huang; Y Yang
Journal:  J Tongji Med Univ       Date:  2001

10.  Relationship of structure and biological activity of monosaccharide lipid A analogues to induction of nitric oxide production by murine macrophage RAW264.7 cells.

Authors:  K Funatogawa; M Matsuura; M Nakano; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.